Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California


Recent News and Articles on the Keywords: cancer + rad9 + target  Related to the article below (Last Update: 12/1/2008)

 News results: Standard Version | Text Version | Image Version  
Your search - cancer + rad9 + target - did not match any documents.
Suggestions:
Make sure all words are spelled correctly.
Try different keywords.
Try more general keywords.
Try fewer keywords.
Try Google Blog Search.
Also, you can browse today's headlines on the Google News homepage.
Source: Google News


 

Recent News and Articles on the Keywords: cancer + 0.34 + therapy  Related to the article below (Last Update: 8/7/2008)

Biomarkers in Targeted Therapy for Colorectal Cancer
Medscape (subscription) - Jul 22, 2008
The ability to tailor biologic therapy based on the status of tumor biomarkers has intrigued cancer researchers in recent years. ...
Source: Google News

Hormone Replacement Therapy After a Diagnosis of Breast Cancer in Relation to Recurrence and … -
ES O'Meara, MA Rossing, JR Daling, JG Elmore, WE … - jnci, 2001 - jnci.oxfordjournals.org
... of 174 users and 695 nonusers of hormone replacement therapy (HRT) after ... associated
with ever use of HRT after breast cancer of 0.58 (95% CI = 0.34 to 0.98 ...

Does Locoregional Radiation Therapy Improve Survival in Breast Cancer? A Meta-Analysis -
TJ Whelan, J Julian, J Wright, AR Jadad, ML Levine - Journal of Clinical Oncology, 2000 - jco.ascopubs.org
... women with node-positive breast cancer treated with ... The type of systemic therapy
received, sites irradiated ... ratio, 0.25; 95% CI, 0.19 to 0.34), and mortality ...

Primary surgical therapy of ovarian cancer: how much and when. -
ME Potter, EE Partridge, KD Hatch, SJ Soong, JM … - Gynecol Oncol, 1991 - ncbi.nlm.nih.gov
Primary surgical therapy of ovarian cancer: how much and ... who did not undergo these
procedures and yet had residual disease remaining (P = 0.7 and P = 0.34). ...

Blood Flow and Metabolism in Locally Advanced Breast Cancer: Relationship to Response to Therapy -
DA Mankoff, LK Dunnwald, JR Gralow, GK Ellis, A … - Journal of Nuclear Medicine, 2002 - Soc Nuclear Med
... had well-differentiated (grade I) lobular breast cancer. ... low (blood flow 0.27 and
0.34 mL/min/g ... Comparison with Response to Therapy The relationships between ...

… and Its Inhibitor PAI-1: Predictors of Poor Response to Tamoxifen Therapy in Recurrent Breast Cancer -
JA Foekens, MP Look, HA Peters, WLJ van Putten, H … - jnci, 1995 - jnci.oxfordjournals.org
... of tamoxifen treatment in breast cancer patients with ... in the study received tamoxifen
therapy upon relapse ... 26% response; odds ratio [OR] = 0.34; 95% confidence ...

Estrogen Replacement Therapy and Breast Cancer Survival in a Large Screening Study -
C Schairer, M Gail, C Byrne, PS Rosenberg, SR … - jnci, 1999 - jnci.oxfordjournals.org
... 1. Unadjusted cumulative crude breast cancer mortality (%) according to ... and current
users of estrogen replacement therapy. ... 0.30 (95% CI = 0.25-0.34), and 0.32 ...

[PDF] Second Cancers After Adjuvant Tamoxifen Therapy for Breast Cancer -
RE Curtis, JD Boice, DA Shriner, BF Hankey, JF … - jnci, 1996 - jnci.oxfordjournals.org
... Initial breast cancer therapy 95% confidence interval 1.03-1.21 0.66-2.12 0.86-1.19
0.54-3.24 0.69-2.03 0.83-1.30 0.66-1.49 0.22-3.20 0.34-2.05 0.43-1.28 0.80 ...
-

… with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer -
WA See, MP Wirth, DG McLeod, P Iversen, I Klimberg … - The Journal of Urology, 2002 - Elsevier
... with localized or locally advanced prostate cancer were randomized ... hazards ratio
0.43; 95% CI 0.34, 0.55; p ... 0.001) for patients who received therapy of primary ...

Differences in initial treatment patterns and outcomes of lung cancer in the elderly. -
TJ Smith, L Penberthy, CE Desch, M Whittemore, C … - Lung Cancer, 1995 - ncbi.nlm.nih.gov
... incident cases of NSCLC from the Virginia Cancer Registry (VCR ... 0.43), thoracotomy
(OR 0.27; CI 0.21, 0.34), and more use of radiation therapy compared to ...

… -term surveillance of mortality and cancer incidence in women receiving hormone replacemen therapy -
K HUNT, M VESSEY, K MCPHERSON, M COLEMAN - BJOG: An International Journal of Obstetrics & Gynaecology, 1987 - Blackwell Synergy
... The eight observed deaths from ovarian cancer are, however ... say that most of the
?opposed? therapy received by ... ratios are low, varying between 0.34 and 0.69 ...

Source: Google Scholar
 
 

Rad9 as a potential target for cancer therapy

Researchers at Washington University School of Medicine in St. Louis found that inactivating a protein called mammalian Rad9 could make cancer cells easier to kill with ionizing radiation.

The researchers found that Rad9 is a "repairman" that fixes dangerous breaks in the DNA double helix.
They found Rad9 is especially active in telomeres, the protective ends of chromosomes.

Because of this new role, Rad9 has gained the researchers' interest as a potential target for cancer therapy -- knocking out Rad9 would enhance the power of radiation treatments by making it easier for radiation to inflict fatal damage to a tumor's genetic material.

" Our study suggests that if we could inactivate Rad9 in tumor cells, we would be able to kill them with a very low dose of radiation and gain a therapeutic advantage," says senior author Tej K. Pandita, at Washington University School of Medicine and Barnes-Jewish Hospital.

The study revealed that Rad9 proteins interact with chromosomes' telomeres, which are special structures at the ends of chromosomes that protect them from fusion or degradation. Specifically, Rad9 proteins were shown to interact with proteins called telomere binding proteins.
When the scientists inactivated Rad9 in human cells, they saw damage to chromosomes and end-to-end fusion at telomeres. DNA damage and chromosomal fusion can disrupt the cell cycle and cause cell death.
Because radiation treatments increase these incidents, loss of Rad9 in cancer cells could enhance the killing effect of radiation.

Previous research had suggested that Rad9 maintains cell cycle checkpoint controls -- researchers thought that the protein helped monitor DNA during replication and signaled the cell to stop its growth cycle if damage was detected. That role is not supported by this current research, and it has become evident that Rad9 directs the repair of DNA damage instead, according to Pandita.

" We saw that Rad9 stabilizes telomeres, and because we aren't yet sure how it does it, we will continue to study how Rad9 influences the telomere structure," Pandita says. " We speculate that without Rad9, some of the other proteins associated with the telomeric structure become delocalized, exposing the DNA at the ends of chromosomes."

In addition to being able to enhance radiosensitization of cancerous tissues by inactivating Rad9, the researchers would like to be able to identify people with mutations in Rad9 because such mutations could predispose a person to cancer.

" If Rad9 isn't functioning properly in cells, it can lead to genomic instability and result in the malignant transformation of cells," Pandita says. " In fact, fusions at the telomeric ends of chromosomes like those seen in the absence of Rad9 appear frequently in tumor tissues."

The study's findings place Rad9 at an important juncture: its function is vital to the health of cells, and this makes it a key vulnerability to exploit for cancer therapy.

Source: Washington University School of Medicine, 2006

 
 
 
Google
Web www.iconocast.com
 
 

 

Continue News With: News9A ;

 

 

ALL THE NEWS : News1 ; News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 © 2002-2006

Keywords:

Contact Iconocast

Home Page